業績

論文の業績 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 取得特許一覧

2017

1
Sakata F, Ito Y, Mizuno M, Sawai A, Suzuki Y, Tomita T, Tawada M, Tanaka A, Hirayama A, Sagara A, Wada T, Maruyama S, Soga T, Matsuo S, Imai E, Takei Y.
Sodium chloride promotes tissue inflammation via osmotic stimuli in sub-total-nephrectomized mice.
Laboratory Investigation, 97: 432-446 (2017).
2
Mihara K, Yoshida T, Takei Y, Sasaki N, Takihara Y, Kuroda J, Ichinohe T.
T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
Journal of Hematology & Oncology
, 10: 116 (2017).
3
Tomita T, Arai S, Kitada K, Mizuno M, Suzuki Y, Sakata F, Nakano D, Hiramoto E, Takei Y, Maruyama S, Nishiyama A, Matsuo S, Miyazaki T, Ito Y.
Apoptosis inhibitor of macrophage ameliorates fungus-induced peritoneal injury model in mice.
Scientific Reports
, 7: 6450 (2017).
4
Takei Y*, Suzuki A, Mihara K, Yanagihara K.
(*, corresponding author).
The microRNA miR-516a-3p regulates the Wnt pathway by targeting extracellular sulfatase 1 in human scirrhous gastric cancers: Anti-metastatic therapy via miRNA-based medicine.
Medical Research Archives, 5: 1-19 (2017).
5
Kariya T, Nishimura H, Mizuno M, Suzuki Y, Sakata F, Maruyama S, Takei Y, Ito Y.
TGF-β-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis.
American Journal of Physiology-Renal Physiology, in press (2017).

2016

1
Tawada M, Ito Y, Hamada C, Honda K, Mizuno M, Suzuki Y, Sakata F, Terabayashi T, Matsukawa Y, Maruyama S, Imai E, Matsuo S, Takei Y.
Vascular endothelial cell injury is an important factor in the development of encapsulating peritoneal sclerosis in long-term peritoneal dialysis patients.
PLoS One, 11: e0154644 (2016).
2
Mihara K, Yoshida T, Ishida S, Takei Y, Kitanaka A, Shimoda K, Morishita K, Takihara Y, Ichinohe T.
All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors.
Blood Cancer Journal, 6:e421 (2016).
3
Makino Y, Hamamura K, Takei Y, Bhuiyan RH, Ohkawa Y, Ohmi Y, Nakashima H, Furukawa K, Furukawa K.
A therapeutic trial of human melanomas with combined small interfering RNAs targeting adaptor molecules p130Cas and paxillin activated under expression of ganglioside GD3.
Biochimica et Biophysica Acta - General Subjects, 1860:1753-1763 (2016).
4
Yoshida T, Mihara K, Takei Y, Yanagihara K, Kubo T, Bhattacharyya J, Imai C, Mino T, Takihara Y, Ichinohe T.
All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia.
Clinical & Translational Immunology, 5: e116 (2016).

2015

1
Yuan Y, Makita N, Cao D, Mihara K, Kadomatsu K, Takei Y*.
(*, corresponding author).
Atelocollagen-mediated intravenous siRNA delivery specific to tumor tissues orthotopically xenografted in prostates of nude mice, and its anticancer effects.
Nucleic Acid Therapeutics, 25:85-94 (2015).
2
Terabayashi T, Ito Y, Mizuno M, Suzuki Y, Kinashi H, Sakata F, Tomita T, Iguchi D, Tawada M, Nishio R, Maruyama S, Imai E, Matsuo S, Takei Y.
Vascular endothelial growth factor receptor-3 is a novel target to improve net ultrafiltration in methylglyoxal-induced peritoneal injury.
Laboratory Investigation, 95:1029-1043 (2015).

2014

1
Takei Y*, Ohnishi N, Kisaka M, Mihara K.
(*, corresponding author).
Determination of abnormally expressed microRNAs in bone marrow smears from patients with follicular lymphomas.
SpringerPlus, 3:288 (2014).
2
Takei Y*.
(*, corresponding author).
Electroporation-mediated siRNA delivery into tumors.
Methods in Molecular Biology, 1121:131-138 (2014).
3
Fujimoto I, Takei Y*.
(*, corresponding author).
Atelocollagen-mediated siRNA delivery: future promise for therapeutic application.
Therapeutic Delivery, 5:369-371 (2014).
4
Horibe H, Murakami M, Iohara K, Hayashi Y, Takeuchi N, Takei Y, Kurita K, Nakashima M.
Isolation of a stable subpopulation of mobilized dental pulp stem cells (MDPSCs) with high proliferation, migration, and regeneration potential is independent of age.
PLoS One, 9:e98553 (2014).

2013

1
Kinashi H, Ito Y, Mizuno M, Suzuki Y, Terabayashi T, Nagura F, Hattori R, Matsukawa Y, Mizuno T, Noda Y, Nishimura H, Nishio R, Maruyama S, Imai E, Matsuo S, Takei Y.
TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis.
Journal of the American Society of Nephrology, 24:1627-1642 (2013).
2
Iohara K, Murakami M, Takei Y, Horibe H, Kurita K, Nakamura H, Nakashima M.
Quality assurance of clinical-grade pulp stem cells manufactured in GMP-compliant facility.
The Japanese Journal of Conservative Dentistry, 56:121-129 (2013).
3
Murakami M, Horibe H, Iohara K, Hayashi Y, Osako Y, Takei Y, Nakata K, Motoyama N, Kurita K, Nakashima M.
The use of granulocyte-colony stimulating factor induced mobilization for isolation of dental pulp stem cells with high regenerative potential.
Biomaterials, 34:9036-9047 (2013).

2012

1
Inaba S, Nagahara S, Makita N, Tarumi Y, Ishimoto T, Matsuo S, Kadomatsu K, Takei Y*.
(*, corresponding author).
Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals.
Molecular Therapy, 20:356-366 (2012).
2
Koide, N, Yasuda K, Kadomatsu K, Takei Y*.
(*, corresponding author).
Establishment and optimal culture conditions of microRNA-induced pluripotent stem cells generated from HEK293 cells via transfection of microRNA-302s expression vector.
Nagoya Journal of Medical Science, 74:157-165 (2012).
3
Suzuki Y, Ito Y, Mizuno M, Kinashi H, Sawai A, Noda Y, Mizuno T, Shimizu H, Fujita Y, Matsui K, Maruyama S, Imai E, Matsuo S, Takei Y.
Transforming growth factor-β induces vascular endothelial growth factor-C expression leading to lymphangiogenesis in rat unilateral ureteral obstruction.
Kidney International, 81:865-879 (2012).
4
Kubo T, Takei Y, Mihara K, Yanagihara K, Seyama T.
Amino-modified and lipid-conjugated dicer-substrate siRNA enhances RNAi efficacy.
Bioconjugate Chemistry, 23:164-173 (2012).
5
Kubo T, Yanagihara K, Takei Y, Mihara K, Sato Y, Seyama T.
Lipid-conjugated 27-nucleotide double-stranded RNAs with dicer-substrate potency enhance RNAi-mediated gene silencing.
Molecular Pharmaceutics, 9:1374-1383 (2012).
6
Kubo T, Yanagihara K, Takei Y, Mihara K, Sato Y, Seyama T.
SiRNAs conjugated with aromatic compounds induce RISC-mediated antisense strand selection and strong gene-silencing activity.
Biochemical and Biophysical Research Communications, 426:571-577 (2012).
7
Mihara K, Bhattacharyya J, Kitanaka A, Yanagihara K, Kubo T, Takei Y, Asaoku H, Takihara Y, Kimura A.
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells.
Leukemia, 26:365-367 (2012).
8
Bhattacharyya J, Mihara K, Kitanaka A, Yanagihara K, Kubo T, Takei Y, Kimura A, Takihara Y. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1.
Blood Cancer Journal, 2:e75 (2012).
9
Bhattacharyya J, Mihara K, Ohtsubo M, Yasunaga S, Takei Y, Yanagihara K, Sakai A, Hoshi M, Takihara Y, Kimura A.
Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression.
Cancer Science, 103:34-41 (2012).

2011

1
Takei Y*, Takigahira M, Mihara K, Tarumi Y, Yanagihara K.
(*, corresponding author).
The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer.
Cancer Research, 71:1442-1453 (2011).
2
Kubo T, Yanagihara K, Takei Y, Mihara K, Morita Y, Seyama T.
Palmitic acid-conjugated 21-nt siRNA enhances gene-silencing activity.
Molecular Pharmaceutics, 8:2193-2203 (2011).
3
Sakamoto K, Bu G, Chen S, Takei Y, Hibi K, Kodera Y, MaCormick LM, Nakao A, Noda M, Muramatsu T, Kadomatsu K.
The premature ligand-receptor interaction during biosynthesis limits the production of growth factor midkine and its receptor LDL receptor-related protein 1 (LRP1).
Journal of Biological Chemistry, 286:8405-8413 (2011).
4
Sawai A, Ito Y, Mizuno M, Suzuki Y, Toda S, Ito I, Hattori R, Matsukawa Y, Gotoh M, Takei Y, Yuzawa Y, Matsuo S.
Peritoneal macrophage infiltration is correlated with baseline peritoneal solute transport rate in peritoneal dialysis patients.
Nephrology Dialysis Transplantation, 26:2322-2332 (2011).

2010

1
Nagano A, Ohno T, Shimizu K, Hara A, Yamamoto T, Kawai G, Saitou M, Takigami I, Matsuhashi A, Yamada K, Takei Y.
EWS/Fli-1 chimeric fusion gene up-regulates vascular endothelial growth factor-A.
International Journal of Cancer, 126:2790-2798 (2010).
2
Mihara K, Yanagihara K, Takigahira M, Kitanaka A, Imai C, Bhattacharyya J, Kubo T, Takei Y, Yasunaga S, Takihara Y, Kimura A.
Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin’s lymphoma.
British Journal of Haematology, 151:37-46 (2010).

2009

1
Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu, K, Takei Y*.
(*, corresponding author).
Systemic delivery of siRNA specific to tumor mediated by atelocollagen: Combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
International Journal of Cancer, 125:2978-2990 (2009).
2
Sakamoto I, Ito Y, Mizuno M, Suzuki Y, Sawai A, Tanaka A, Maruyama S, Takei Y, Yuzawa Y, Matsuo S.
Lymphatic vessels develop in tubulo-interstitial fibrosis.
Kidney Internatinal, 75:828-838 (2009).

2008

1
Takei Y*, Nemoto T, Mu P, Fujishima F, Ishimoto T, Hayakawa Y, Yuzawa Y, Matsuo S, Muramatsu T, Kadomatsu K.
(*, corresponding author).
In vivo silencing of a molecular target by short interfering RNA electroporation: Tumor vascularization correlates to delivery efficiency.
Molecular Cancer Therapeutics, 7:211-221 (2008).
2
Ishimoto T, Takei Y*, Yuzawa Y, Hanai K, Nagahara S, Tarumi Y, Matsuo S, Kadomatsu K.
(*, corresponding author).
Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity.
Molecular Therapy, 16:387-95 (2008).
3
Uehara S, Shimada N, Takeda Y, Koyama Y, Takei Y, Ando H, Satoh S, Uno A, Sakurai K.
3’ Poly(dA)-tailed thrombin DNA aptamer to increase DNase-resistance and clotting inhibitory activity.
Bulletin of the Chemical Society of Japan, 81:1485-1491 (2008).

2007

1
Chen S, Bu G, Takei Y, Sakamoto K, Ikematsu S, Muramatsu T, Kadomatsu K.
Midkine and LDL receptor-related protein 1 contribute to the anchorage-independent cell growth of cancer cells.
Journal of Cell Science, 120:4009-4015 (2007).

2006

1
Takei Y*, Kadomatsu K, Goto T, Muramatsu T.
(*, corresponding author).
Combinational antitumor effect of siRNA as to midkine and paclitaxel on growth of human prostate cancer xenografts.
Cancer, 107:864-873 (2006).
2
Banno H, Takei Y, Muramatsu T, Komori K, Kadomatsu K.
Controlled release of siRNA as to midkine attenuates intimal hyperplasia in vein grafts.
Journal of Vascular Surgery, 44:633-641 (2006).
3
Kosugi T, Yuzawa Y, Sato W, Kawai H, Matsuo S, Takei Y, Muramatsu T, Kadomatsu K.  Growth factor midkine is involved in the pathogenesis of diabetic nephropathy.
American Journal of Pathology, 168:9-19 (2006).
4
Fujii T, Saito M, Iwasaki E, Ochiya T, Takei Y, Hayashi S, Ono A, Hirao N, Nakamura M, Kubushiro K, Tsukazaki K, Aoki D.
Intratumor injection of small interfering RNA targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer.
International Journal of Oncology, 29:541-548 (2006).

2005

1
Takei Y*, Kadomatsu K, Yuasa K, Sato W, Muramatsu T.
(*, corresponding author).
Morpholino antisense oligomer targeting human midkine: its application for cancer therapy.
International Journal of Cancer, 114:490-497 (2005).
2
Takei Y*, Kadomatsu K.
(*, corresponding author).
In vivo delivery technique of nucleic acid compounds using atelocollagen: Its use in cancer therapeutics targeted at the heparin-binding growth factor midkine.
Gene Therapy and Molecular Biology, 9:257-264 (2005).
3
Sato W, Takei Y, Yuzawa Y, Matsuo S, Kadomatsu K, Muramatsu T.
Midkine antisense oligodeoxynucleotide inhibits renal damage induced by ischemic reperfusion.
Kidney International, 67:1330-1339 (2005).
4
Hayashi K, Banno H, Kadomatsu K, Takei Y, Komori K, Muramatsu T.
Antisense oligonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury.
American Journal of Physiology: Heart and Circulatory Physiology, 288:2203-2209 (2005).

2004

1
Takei Y*, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T.
(*, corresponding author).
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics.
Cancer Research, 64:3365-3370 (2004).
2
Kawai H, Sato W, Yuzawa Y, Kosugi T, Matsuo S, Takei Y, Kadomatsu K, Muramatsu T.
Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage.
American Journal of Pathology, 165:1603-1612 (2004).

取得特許一覧

1
武井佳史、藤島達也、村松喬、門松健治 
エレクトロポレーション装置の制御方法
特許5176104号(登録日:2013年1月18日 日本国)
国際出願番号:PCT/JP/2006/314059
2
山本徳則、小出直史、後藤百万、武井佳史
脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤
特許第5035737号(登録日:2012年7月13日 日本国)
国際出願番号:PCT/JP/2010/071633
3
山本徳則、小出直史、武井佳史、松川宣久、舟橋康人、後藤百万
脂肪組織由来間葉系幹細胞を含有する、勃起不全又は尿意障害用の細胞製剤
特許第4953335号(登録日:2012年3月23日 日本国)
国際出願番号:PCT/JP/2010/065271
Cell preparation for erectile dysfunction or sensory disorders of the lower urinary tract containing adipose tissue derived mesenchymal stem cells.
米国特許取得 US 8,808,688 (August 19, 2014)
4
武井佳史、門松健治、村松喬
siRNAを用いたヒト血管内皮増殖因子の発現の強い抑制
特許第4480125号(登録日:2010年3月26日 日本国)
5
武井佳史、門松健治、村松喬
アンチセンスオリゴヌクレオチドの新規作成法
特許第4048296号(登録日:2007年12月7日 日本国)
6
勝崎智之、武井佳史、屋鋪哲也、舟岡宏幸、白井晶、大軽靖彦、賀登志朗、石井泰雄
スルトプリド誘導体及び抗スルトプリド抗体
特許第3408158号(登録日:2003年3月14日 日本国)